Invion Share Price and Company Fundamentals
Last traded: Today at 4:37 AM
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
0.87
Dividend yield
-
Beta
0.86
Market cap
$7.19M
Enterprise value
$6.32M
Company profile
| Industry / Sector | Drug Manufacturers - Specialty & Generic / Healthcare |
|---|---|
| Website | https://www.inviongroup.com |
| Mailing address | 385 Bourke Street Suite 2, Level 11 Melbourne VIC 3000 Australia |
| Phone / Fax | 61 3 9692 7222 / |
Dividends
More: Invion Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Invion paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.IVX dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Invion.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Thian Chew | Executive Chairman & CEO | ||
| Ms. Melanie Jaye Leydin B.Bus, C.A. | CFO, Company Secretary & Non-Executive Director | 52 | |
| Dr. Dean Naylor | Head of Intellectual Property Development |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-230001.27%
Return on assets
-44.16%
Return on equity
-77.64%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Invion is 7.19M and its enterprise value is 6.32M. The enterprise value to revenue ratio of IVX is 2097.70. The enterprise value to EBITDA ratio of IVX is -1.58.
The IVX's stocks Beta value is 0.86 making it 14% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Invion (IVX)
Invion (ASX:IVX) Frequently Asked Questions
1. What is Invion's Stock Symbol?
Invion trades on ASX under the ticker symbol "IVX".
2. What is Invion's stock price today?
One share of IVX stock can currently be purchased for approximately $0.084.
3. How can I contact Invion?
Invion's mailing address is 385 Bourke Street Suite 2, Level 11 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9692 7222.
4. What is Invion's official website?
The official website of Invion is https://www.inviongroup.com.